A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer

European Journal of Cancer Part A

Volumn 33, Issue 4, 1997, Pages 592-595

  Bolis, G ^a,b   Scarfone, G ^a   Zanaboni, F ^b   Villa, A ^a   Presti, M ^c   Melpignano, M ^d   Ferraris, C ^a   Tateo, S ^c   Guarnerio, P ^a   Gentile, A ^e   Parazzini, F ^a,f  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e BRISTOL MYERS SQUIBB   (United States)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

carboplatin; ovarian cancer; paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYPERSENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM PERMISSIBLE DOSE; MYALGIA; NEUROTOXICITY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0031006284     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00495-9     Document Type: Article

References (17)

1. Rowinsky EK, Onetto N, Canetta R, et al. Taxol: the first of the takanes, an important new class of antitumor agents. Semin Oncol 1992, 19, 646-662.
2. McGuire WP. Taxol: a new drug with significant activity as salvage therapy in advanced epithelial ovarian carcinoma. Gynecol Oncol 1993, 51, 78-85.
3. McGuire WP, Hoskins WJ, Brady MF, et al. Taxol and cisplatin (TP) improves outcomes in advanced ovarian cancer (AOC) as compared to cytoxan and cisplatin (CP). Proc Am Soc Clin Oncol 1995, 14, 771 (abstract).
4. Ozols RF, Kilpatrick D, O'Dwyer P, et al. Phase I and pharmacokinetic study of taxol (T) and carboplatin (C) in previously untreated patients (PTS) with advanced epithelial ovarian cancer (OC): a pilot study of the gynecologic oncology group. Proc Am Soc Clin Oncol 1993, 12, 824 (abstract).
5. Ten Bokkel Huinink WW, Veenhof CHN, et al. Carboplatin and paclitaxel (taxol) in patients with advanced ovarian cancer, a dose-finding study. Proc ESMO 1994, 495, 99 (abstract).
6. Bissett D, Kaye SB. Taxol and taxotere - current status and future prospects. Eur J Cancer 1993, 29A, 1228-1231.
7. Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 1963, 58, 690-700.
8. Bolis G. Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Semin Oncol 1995, 22, 32-36.
9. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7, 1748-1756.
10. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991, 9, 1692-1703.
11. Mangioni C, Bolis G, Pecorelli S, et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 1989, 81, 1464-1471.
12. Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and G-CSF in patients with refractory ovarian cancer. J Clin Oncol 1992, 10, 1165-1170.
13. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987, 5, 756-757.
14. Levin L, Hryniuk W. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol 1987, 14(Suppl. 4), 12-19.
15. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994, 12, 2654-2666.
16. Sarosy G, Kohn E, Link C, et al. Taxol dose intensification (D.I.) in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 1992, 11, 716 (abstract).
17. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al. Long-term survival in ovarian cancer. Eur J Cancer 1991, 27, 1367-1372.